

1

2 **Molecular mechanism regulating transcriptional control of the *hig***  
3 **toxin-antitoxin locus of antibiotic-resistance plasmid Rts1 from**  
4 ***Proteus vulgaris***

5

6 Ian Pavelich<sup>1,2</sup>, Marc A. Schureck<sup>1</sup>, Dongxue Wang<sup>1</sup>, Eric D. Hoffer<sup>1</sup>, Michelle Boamah<sup>1</sup>,  
7 Nina Onuoha<sup>1</sup>, Stacey J. Miles<sup>1</sup>, C. Denise Okafor<sup>3</sup>, and Christine M. Dunham<sup>1\*</sup>

8

9 <sup>1</sup>Department of Biochemistry and the Emory Antibiotic Resistance Center, Emory  
10 University School of Medicine, Atlanta, Georgia, 30322

11 <sup>2</sup>Department of Chemistry, Emory University, Atlanta, Georgia, 30322

12 <sup>3</sup>Department of Biochemistry and Molecular Biology, Pennsylvania State University,  
13 University Park, Pennsylvania 16802

14

15 These authors contributed equally.

16 \*To whom correspondence should be addressed: Tel: 1-404-712-1756; Fax: 1-404-727-  
17 2738; Email: [christine.m.dunham@emory.edu](mailto:christine.m.dunham@emory.edu)

18 Data deposition: Crystallography, atomic coordinates, and structure factors have been  
19 deposited in the Protein Data Bank, [www.pdb.org](http://www.pdb.org) (PDB codes 6W6U, 6WFP)

20

21 **Running title:** Regulation of *P. vulgaris* HigBHigA toxin-antitoxin

22

23 **Keywords:** toxin-antitoxin complexes, gene expression regulation, transcriptional  
24 repression, DNA-binding proteins, X-ray crystallography, *Proteus vulgaris*

25 **ABSTRACT**

26 Regulation of ubiquitous bacterial type II toxin-antitoxin (TA) gene pairs occurs via a negative  
27 feedback loop whereby their expression is typically responsive to changing levels of toxins  
28 at the transcriptional level similar to a molecular rheostat. While this mechanism can explain  
29 how certain TA complexes are regulated, accumulating evidence suggests diversity in this  
30 regulation. One system for which the negative feedback loop is not well defined is the  
31 plasmid-encoded HigBHigA TA pair originally identified in a post-operative infection with  
32 antibiotic resistant *Proteus vulgaris*. In contrast to other type II TA modules, each *hig*  
33 operator functions independently and excess toxin does not contribute to increased  
34 transcription *in vivo*. Structures of two different oligomeric complexes of HigBHigA bound to  
35 its operator DNA reveal similar interactions are maintained suggesting plasticity in how *hig*  
36 is repressed. Consistent with this result, molecular dynamic simulations reveal both  
37 oligomeric states exhibit similar dynamics. Further, engineering a dedicated trimeric  
38 HigBHigA complex does not regulate transcriptional repression. We propose that HigBHigA  
39 functions via a simple on/off transcriptional switch regulated by antitoxin proteolysis rather  
40 than a molecular rheostat. The present studies thus expand the known diversity of how these  
41 abundant bacterial protein pairs are regulated.

42

43

44

45

46

47

48

49

50 **IMPORTANCE**

51 Bacteria respond to various stimuli by rapidly regulating gene expression to control growth.  
52 The diversity in how bacteria inhibit growth is exemplified by the abundance and diversity of  
53 toxin-antitoxin (TA) gene pairs. To tightly regulate their own expression, antitoxin proteins  
54 function as transcriptional autorepressors with additional regulation imparted by  
55 responsiveness of the system to toxin concentrations, similar to a molecular rheostat.  
56 However, some TAs do not appear to be responsive to changing levels of toxin. To expand  
57 our understanding of diverse TAs, we studied the regulation of a structurally distinct TA  
58 called host inhibition of growth (HigBA) originally discovered on the antibiotic resistance Rts1  
59 plasmid associated with *Proteus vulgaris*. We find that the *hig* operon is regulated via a  
60 simple on/off transcriptional switch that is inalcitrant to changing toxin levels. These results  
61 expand the known mechanistic diversity of how TA pairs regulate their expression.

62

63

64

65

66

67

68

69

70

71

72

73

74

## 75 INTRODUCTION

76 Bacterial toxin-antitoxin (TA) genes are bicistronic operons found in mobile genetic elements  
77 and bacterial chromosomes (1-3). Type II TA modules consist of toxin and antitoxin protein  
78 components that form architecturally diverse macromolecular complexes in the absence of  
79 external stimuli and during nutrient-rich growth. Although these gene pairs were first  
80 identified on plasmids and in bacteriophages (4-9), TAs are highly abundant in free-living  
81 bacteria where they appear to have different functions. In their role in plasmid maintenance,  
82 the toxin component can induce post-segregational killing if both genes are not inherited (6).  
83 In the past few years, conflicting experimental data on the endogenous activities of TAs have  
84 led to ambiguity and controversy surrounding their roles in bacterial physiology (10).

85 Regulation of type II TA pairs frequently occurs at the transcriptional level via a  
86 negative feedback loop (10-12). Antitoxin proteins contain a DNA-binding motif and repress  
87 at operator sites that overlap with promoters of TA genes. Toxin proteins are either recruited  
88 to their cognate antitoxins bound at these operator sites or bind to operators as TA  
89 complexes where they function as co-repressors, allowing the system to be responsive to  
90 changes in toxin expression levels. Further, TAs can form different oligomeric complexes  
91 when bound at operator sites that alter their binding thermodynamics to result in a gradient  
92 of the transcriptional response similar to a molecular rheostat (13, 14). This response  
93 gradient can also be influenced by cooperative TA binding at adjacent operator sites; this  
94 process is known as “conditional cooperativity” (15-18). However, this model is dependent  
95 on the architectural organization of TAs pairs which can diverge significantly (12, 19). Thus,  
96 it is unclear if conditional cooperativity can explain the regulation of all type II TA systems.

97 The structural diversity and distinct toxin- and DNA-binding motifs of different type II  
98 antitoxin proteins may partially explain why they can exert different mechanisms of  
99 autoregulation (11). Antitoxins contain ribbon-helix-helix (RHH), helix-turn-helix (HTH),

100 Phd/YefM or SpoVT/AbrB DNA-binding motifs, with RHH and HTH being the most common  
101 (20-26). The type of DNA binding motif affects transcriptional repression. HTH-containing  
102 antitoxins contain a complete DNA-binding motif while RHH-containing antitoxins contain a  
103 half site requiring antitoxin dimerization for DNA binding. TA operons usually contain multiple  
104 operator sites and antitoxin binding at adjacent sites can lead to cooperativity and an  
105 increase in transcriptional repression (17, 18, 27). Antitoxins are particularly susceptible to  
106 proteases especially during changing cellular conditions (28). This reduction in antitoxin  
107 concentration increases free toxin levels that when free, can inhibit growth. Free toxin can  
108 also interact with antitoxins bound at their operators changing the oligomeric state of the TA  
109 complex during repression. These oligomeric state changes, in turn, can lead to differences  
110 in the ability of TAs to bind their operator and influence the extent of repression; effectively  
111 this responsiveness allows the system to function as a molecular rheostat (**Fig. 1**). In  
112 contrast, other TA systems do not appear to be responsive to changing levels of toxin and  
113 instead are simple on/off transcriptional switches (29, 30). While there exists some  
114 experimental evidence that distinguishes between the molecular rheostat and the on/off  
115 switch modes of regulation, at present the molecular basis for each mechanism is  
116 ambiguous because there is little or no structural evidence as a foundation for each model.

117       The *host inhibition of growth* BA (*higBA*) TA module seems to function as an on/off  
118 switch. The HigBHigA pair was first identified on the antibiotic-resistance plasmid Rts1  
119 associated with *Proteus vulgaris* and discovered post-operatively in an urinary tract infection  
120 (31, 32) (we call this TA pair “HigBHigA” to denote both the HigB toxin and HigA antitoxin  
121 proteins). The HigB toxin belongs to the RelE family of toxins, resembles a microbial  
122 ribonuclease and cleaves mRNA substrates bound to a translating ribosome (26, 33-35).  
123 Although there are HigBHigA TA pairs found chromosomally and these HigB toxins are also  
124 RelE family members (36, 37), the structural organization and the regulation of these

125 systems compared to the *P. vulgaris* associated module seems to be different (26). While  
126 all known HigA homologs contain a HTH DNA-binding motif, the *P. vulgaris* associated  
127 antitoxin binds to each of its operator sites (O1 and O2) in a non-cooperative manner (26,  
128 38). Here, we test the two models of transcriptional regulation, rheostat versus on/off switch,  
129 to determine the molecular mechanism of action of HigBHigA.

130

## 131 RESULTS

132 **Transcriptional repression at each operator is independently regulated.** The *hig*  
133 promoter (*Phig*) is negatively autoregulated by the HigBHigA complex binding at operators  
134 O1 and O2 that overlap with the -35 and -10 promoter sites (32) (**Fig. 2A**). The HigBHigA  
135 complex forms a tetrameric assembly with two HigB monomers and a HigA dimer  
136 ( $\text{HigB}_2\text{HigA}_2$ ) (26). Each HigA antitoxin contains a single HTH DNA-binding motif and forms  
137 an obligate dimer, meaning that two HigA antitoxins in one  $\text{HigB}_2\text{HigA}_2$  complex bind two  
138 inverted repeats of a single DNA operator (26, 38). To determine if we could build oligomeric  
139 complexes *in vitro*, we monitored the binding of the  $\text{HigB}_2\text{HigA}_2$  complex to *hig* (O1 and O2)  
140 using an electrophoretic mobility shift assay (EMSA) (**Fig. 2B**). The  $\text{HigB}_2\text{HigA}_2$  complex  
141 was purified according to previously published protocols and the DNA probe used in the  
142 EMSA consists of the entire 61 basepair (bp) operator region (**Table S1**). Titration of  
143  $\text{HigB}_2\text{HigA}_2$  with a constant amount of *hig* causes two molecular weight shifts, indicating  
144 binding of  $\text{HigB}_2\text{HigA}_2$  at each operator site (**Fig. 2B**, top). To determine whether  $\text{HigB}_2\text{HigA}_2$   
145 binds with a higher affinity to either O1 or O2, all 21 nucleotides in each operator were  
146 randomized individually (38). Each of these 21 nucleotides located in either O1 or O2 were  
147 previously shown to be protected upon HigA binding (39). Therefore any change in the  
148 mobility of the DNA band using a scrambled O1 or O2 would represent binding of  $\text{HigB}_2\text{HigA}_2$   
149 to a single operator.  $\text{HigB}_2\text{HigA}_2$  binds to each of the two sites represented as a single

150 molecular weight shift and both result in similar dissociation binding constants ( $0.36 \pm 0.09$   
151  $\mu\text{M}$  for O1 and  $0.24 \pm 0.04 \mu\text{M}$  for O2) (**Fig. 2B**, middle and lower; **Table S2**). These data  
152 indicate that HigB<sub>2</sub>HigA<sub>2</sub> recognizes each operator independently to form a high affinity  
153 interaction. This observation appears to be an important distinction from other type II TAs  
154 where TA complexes binding at an operator influences the binding of TAs at adjacent  
155 operators (**Fig. 1**).

156 To test whether HigB<sub>2</sub>HigA<sub>2</sub> binding at a single operator results in transcriptional  
157 repression *in vivo*, we designed a series of constructs that encode *lacZ* in three different  
158 contexts: downstream of the *Phig* promoter (pQF50-*Phig-lacZ*), downstream of wild-type  
159 HigA (pQF50-*Phig-higA-lacZ*), or downstream of a C-terminally truncated HigA (pQF50-  
160 *Phig-higA*( $\Delta 84-104$ )-*lacZ*) (**Fig. 2C**). The pQF50-*Phig-lacZ* construct reports on the activity  
161 of *Phig* in the absence of repressor HigA, while the HigA-encoding pQF50-*Phig-higA-lacZ*  
162 construct reports on how expression of HigA represses *Phig*. The third construct serves as  
163 a control as the HigA( $\Delta 84-104$ ) variant is unable to dimerize and bind *Phig* but is comparably  
164 expressed (26, 38). *Phig-lacZ* shows robust  $\beta$ -galactosidase ( $\beta$ -gal) activity which we  
165 normalize to represent complete transcriptional repression (this is represented as 0%  
166 repression; **Fig. 2C**). Expression of HigA efficiently represses *Phig*, whereas HigA( $\Delta 84-104$ )  
167 restores *Phig* activity to near *Phig*-only levels, indicating transcriptional repression is  
168 dependent on HigA expression and dimerization (**Fig. 2C**). To test whether HigA<sub>2</sub> binding to  
169 a single operator region is sufficient for repression, we mutated either O1 or O2 recognition  
170 sequences important for HigA binding (38) and repeated the previously described  $\beta$ -gal  
171 assays. Mutations to either O1 (G<sub>-24</sub>T/C<sub>-30</sub>A) or O2 (G<sub>-8</sub>T/C<sub>-2</sub>A) do not affect HigA<sub>2</sub> repression  
172 at a single mutant *Phig* when compared to the wild-type *Phig* (**Fig. 2C**, compare middle bars  
173 in “O1 variant” and “O2 variant” group to “*Phig*”). These results show that HigA<sub>2</sub> binding at  
174 either O1 or O2 is sufficient for repression (data also presented in Miller Units in **Fig. S1**).

175 Further, these data indicate that HigA<sub>2</sub> binding at each *hig* operator is not cooperative, and  
176 that a single operator is sufficient for transcriptional repression.

177

178 **Addition of HigB destabilizes interactions between HigA and DNA *in vitro*.** The  
179 expression of most type II TA complexes is regulated at the transcriptional level by changing  
180 toxin and antitoxin concentrations as a result of increased proteolysis of the antitoxin during  
181 external stimuli (17, 18, 22). We reasoned that the HigBHigA complex may transcriptionally  
182 repress using a different mechanism because of the structural diversity of the HigA antitoxin.  
183 The unique structure of HigA could influence its interactions with *hig* or HigB toxin binding.  
184 For example, the HigA HTH motif is a complete DNA-binding domain and by extension, the  
185 obligate HigA<sub>2</sub> dimer contains two DNA-binding domains. Other type II antitoxins typically  
186 contain a single DNA-binding motif formed by antitoxin dimerization (**Fig. 1**). These  
187 differences are likely important for the changing of different oligomeric TA complexes bound  
188 to operators allowing the system to respond to changing toxin levels. To test this, we  
189 explored whether the presence of excess HigB changes the molecular interactions of HigA  
190 with the O1-O2 operators (**Fig. 3**). Addition of HigA<sub>2</sub> to O1-O2 results in two shifted bands  
191 of lower mobility, indicative of complexes with a single HigA<sub>2</sub> dimer bound to one operator  
192 (**Fig. 3A, yellow**), or two HigA<sub>2</sub> dimers binding to each operator (**Fig. 3A, orange**).  
193 Increasing amounts of HigB results in the formation of two additional higher molecular weight  
194 species (**Fig. 3A**). In this case, either the HigB monomer binds to each of the HigA<sub>2</sub> dimers  
195 to form a trimeric HigBHigA<sub>2</sub> complex (**Fig. 3A, red**) or both HigB monomers bind to a single  
196 HigA<sub>2</sub> dimer as a tetrameric HigB<sub>2</sub>HigA<sub>2</sub> (**Fig. 3A, purple**). As the HigA<sub>2</sub> dimer is already  
197 bound at both O1 and O2, it is unlikely that the molecular weight species would represent  
198 occupation of only a single operator site. While the third shift may contain a mixed population  
199 of oligomeric states where HigB binds only one HigA<sub>2</sub> dimer (**Fig. 3A, red**), an additional



200 observable migration shift may be difficult to observe. Thus, we assume the slowest  
201 migrating band is a tetrameric HigB<sub>2</sub>HigA<sub>2</sub>-O1-O2 complex. When the molar ratio of HigB to  
202 HigA exceeds one (two HigB monomers to one HigA<sub>2</sub> dimer or 1.0 μM HigB for 0.5 μM HigA<sub>2</sub>  
203 dimer), only free DNA is observed suggesting that excess HigB destabilizes the association  
204 between HigA and DNA. These results appear to be similar to what has been observed with  
205 other type II TA complexes that exhibit regulation via conditional cooperativity (17, 18, 27).

206 To determine whether the instability of the HigBHigA complex with O1-O2 is  
207 dependent upon the occupancy of both O1 and O2, we next tested complex formation on  
208 DNA containing either a scrambled O1 or O2 to prevent HigA<sub>2</sub> binding (same mutation as  
209 used in Fig. 2). Addition of HigA<sub>2</sub> to DNA containing either a scrambled O1 or O2 results in  
210 a slower moving species indicative of the HigA<sub>2</sub> dimer binding at one operator (**Fig. 3C,**  
211 **orange**). Increasing amounts of HigB shows a single, slower moving molecular weight  
212 species (**Fig. 3C, purple**). At this point, we assume the HigBHigA complex is tetrameric  
213 (HigB<sub>2</sub>HigA<sub>2</sub>) given the prior crystal structures (26). Once the HigB to HigA molar ratio almost  
214 exceeds 1 (i.e. 1.0 μM HigB for 0.5 μM HigA<sub>2</sub> dimer), the complex is unstable and DNA is  
215 released. Interestingly, in the context of both O1 and O2 (**Fig. 3A**), the molar ratio of HigB  
216 to HigA needs to exceed 1 however, when only one operator is available, this release of  
217 DNA occurs at slightly less than 1 molar equivalents of HigB and HigA. Therefore, the  
218 instability of HigBHigA binding a single operator appears to be accelerated in the absence  
219 of an adjacent HigBHigA complex.

220  
221 **Structure of HigB<sub>2</sub>HigA<sub>2</sub>-O2 DNA.** To determine how HigBHigA interacts with its operator  
222 DNA, we pursued a high-resolution X-ray crystal structure of HigBHigA bound to a single  
223 operator, O2. We performed crystallization trials using two HigBHigA constructs: a six  
224 histidine (His<sub>6</sub>) affinity tag located at the N terminus of HigB and a His<sub>6</sub> affinity tag located at

225 the C terminus of HigA. Both HigBHigA variants crystallized in the same condition, however,  
226 each resulted in a different oligomeric state of the HigBHigA complex bound to O2. The  
227 HigBHigA-His<sub>6</sub>-O2 complex crystallized in the monoclinic space group C121, was determined  
228 to 2.4 Å resolution by single wavelength anomalous diffraction phasing and contained a  
229 HigA<sub>2</sub> dimer bound to two HigB monomers (**Fig. 4**). The His<sub>6</sub>-HigBHigA-O2 complex  
230 crystallized in the tetragonal space group I4<sub>1</sub>, was determined by molecular replacement  
231 using the previously determined HigA<sub>2</sub> model (PDB code 6CF1) to 2.8 Å resolution and  
232 contained a HigA<sub>2</sub> dimer bound to a single HigB (**Fig. 5; Table S3**). In both structures,  
233 residues 1–91 were built for each HigB monomer (92 total residues) and all nucleotides (1–  
234 21) were built for the O2 DNA duplex (**Fig. S2**). Residues 1–101 and 1–102 in the  
235 HigB<sub>2</sub>HigA<sub>2</sub> structure and residues 1–91 and 1–95 in the HigBHigA<sub>2</sub> structure were modeled  
236 (104 total residues) (**Fig. S2**).

237 The HTH motif in HigA consists of α<sub>2</sub>, loop 3 and α<sub>3</sub> and this region interacts with the  
238 major groove of the operator O2 DNA (**Fig. 4A**). In the tetrameric HigB<sub>2</sub>HigA<sub>2</sub>-O2 structure,  
239 HigA contacts the T<sub>-1</sub>, G<sub>-2</sub>, T<sub>-3</sub>, A<sub>-4</sub> O2 sequence on the *hig* negative strand (38) (**Figs. 4A, B**).  
240 HigA residue Arg40 interacts with the Hoogsteen face of G<sub>-2</sub> to make the only sequence-  
241 specific protein-DNA contact. Residues Thr34 and Thr37 (from α<sub>3</sub>) contact the phosphate of  
242 G<sub>+7</sub> while the sidechains of Ser23 (from loop 2), Ser39 (from α<sub>3</sub>), and Lys45 (from α<sub>3</sub>) are  
243 all within hydrogen bonding distance of nucleotides T<sub>-7</sub>, A<sub>-6</sub>, T<sub>-5</sub>, and T<sub>-4</sub>, respectively which  
244 are located on the opposite DNA strand (**Fig. S3**). Additionally, Ala36 and Thr34 form van  
245 der Waals interactions with the nucleobase C5 methyl of A<sub>-3</sub>. These interactions are similar  
246 to those previously observed in the HigA<sub>2</sub>-O2 DNA interaction (38) and are also present  
247 between HigA and O2 on the opposite strand, indicating that HigB binding to form the  
248 tetrameric HigB<sub>2</sub>HigA<sub>2</sub>-O<sub>2</sub> complex does not change interactions of HigA<sub>2</sub> with O2.

249           The termini of antitoxins are typically intrinsically disordered contributing to their  
250 proteolysis during external stimuli. In the free HigA<sub>2</sub> structure (38), the N terminus is  
251 disordered (**Fig. S4A,B**). Upon HigB binding, the HigA termini becomes ordered both in the  
252 free HigB<sub>2</sub>HigA<sub>2</sub> structure (26) and upon binding DNA (HigB<sub>2</sub>HigA<sub>2</sub>-O2 DNA) (**Fig. 4C; Fig.**  
253 **S4C,D**). The N- and C-termini of HigA form intramolecular interactions in addition to  
254 interactions with  $\alpha$ 1 of an adjacent HigB in the crystal lattice (**Fig. S4A,B**). Specifically, N-  
255 terminal residues Arg2 (side chain) and Gln3 (backbone carbonyl) form salt bridges with C-  
256 terminal residues Glu80 and Arg77, respectively, and these interactions presumably stabilize  
257 the termini. Thus, binding of HigB stabilizes HigA both in the presence or absence of DNA.

258           Comparison of the overall architecture of HigB<sub>2</sub>HigA<sub>2</sub>-O2 DNA to HigB<sub>2</sub>HigA<sub>2</sub> (26) or  
259 HigA<sub>2</sub> (38) reveals subtle changes that may be important for O2 DNA binding and  
260 transcriptional repression. Aligning analogous HigA monomers from the HigB<sub>2</sub>HigA<sub>2</sub>-O2 and  
261 the HigB<sub>2</sub>HigA<sub>2</sub> structures (PDB code 4MCX) reveals a  $\sim 14^\circ$  displacement of the adjacent,  
262 second HigA protomer (**Fig. 4D**). Similarly, comparison of the free HigA<sub>2</sub> dimer (PDB code  
263 6CF1) to HigB<sub>2</sub>HigA<sub>2</sub>-O2 also shows rotation of HigA upon DNA binding, although the  
264 movement is not as large as compared to when HigB is present ( $\sim 8^\circ$  rotation versus a  $\sim 14^\circ$   
265 rotation) (**Fig. S5**). Thus, HigA<sub>2</sub> reorients to bind DNA and HigB binding to a HigA<sub>2</sub>-DNA  
266 complex minimally influences the protein-DNA interface.

267  
268 **Structure of HigBHigA<sub>2</sub>-O2 DNA.** As noted above, both the tetrameric HigB<sub>2</sub>HigA<sub>2</sub>-O2 DNA  
269 and trimeric HigBHigA<sub>2</sub>-O2 DNA crystal forms formed in the same crystallization conditions  
270 and resulted in two different macromolecular structures (**Table S3**). Interestingly, not all of  
271 the interactions seen in tetrameric HigB<sub>2</sub>HigA<sub>2</sub>-DNA are conserved in the trimeric HigBHigA<sub>2</sub>-  
272 O2 structure. While critical interactions of HigA with the T<sub>-1</sub>, G<sub>-2</sub>, T<sub>-3</sub>, A<sub>-4</sub> recognition sequence  
273 are maintained,  $\alpha$ 2 and  $\alpha$ 3 of the HTH DNA-binding motif slightly moves away from O2, no

274 longer positioning Ser23 and Lys45 to hydrogen bond with the phosphates of T<sub>-7</sub> and T<sub>-4</sub>  
275 (**Fig. 5B; Fig. S3**).

276 Global comparison of the HigB<sub>2</sub>HigA<sub>2</sub>-O<sub>2</sub> structure with the HigBHigA<sub>2</sub>-O<sub>2</sub> structure  
277 reveal only a ~1° difference emphasizing how similar the two structures are (**Fig. 5D**).  
278 Likewise there are very little differences in the position of HigA<sub>2</sub> bound to O<sub>2</sub> (38) in the  
279 absence or presence of HigB. Thus, it does not appear that HigB binding influences the  
280 position of HigA<sub>2</sub> on DNA. It appears the largest structural change results from either HigA<sub>2</sub>  
281 or HigB<sub>n</sub>HigA<sub>2</sub> binding to DNA (~14° rotation, where “n” denotes either a single HigB or two  
282 HigB monomers; **Fig. 4D**). Previously we described how HigA N-terminal residues Arg2 and  
283 Gln3 interact with its C-terminal residues Arg77 and Glu80 in the HigB<sub>2</sub>HigA<sub>2</sub>-O<sub>2</sub> structure  
284 (**Fig. 4C**). We find that even a single HigB binding can cause these termini residues to  
285 become ordered (**Fig. S4E**).

286 A curious crystallization note for the trimeric HigBHigA<sub>2</sub>-O<sub>2</sub> complex is that there is  
287 an adjacent molecule in the neighboring asymmetric unit that overlaps with the missing HigB  
288 (**Fig. S6**). This ejection of HigB from the HigBHigA complex is surprising given the known  
289 tight interactions of TA complexes where affinities are typically sub-nanomolar (29, 40-42).  
290 Therefore, we think it is unlikely that the trimeric HigBHigA<sub>2</sub>-O<sub>2</sub> complex results from crystal  
291 packing. Interestingly, the structures of both HigBHigA complexes with the different  
292 placement of the His<sub>6</sub> tag were solved and both found to be tetrameric HigB<sub>2</sub>HigA<sub>2</sub> in the  
293 absence of DNA. Taken together, we propose that there is a mixture of both trimeric and  
294 tetrameric HigBHigA complexes bound to DNA in solution. We next sought to examine the  
295 functional relevance of the trimeric HigBHigA<sub>2</sub>-O<sub>2</sub> complex.

296  
297 **HigB<sub>2</sub>A<sub>2</sub>-O<sub>2</sub> and HigBHigA<sub>2</sub>-O<sub>2</sub> complexes exhibit similar dynamics.** The structure of  
298 the trimeric HigBHigA<sub>2</sub>-O<sub>2</sub> complex is intriguing as most models that describe the

299 transcriptional regulation of type II TA systems conclude that such an oligomeric state is  
300 more stable than the fully loaded complex (18, 21, 42). However, prior to our new structure,  
301 there has been no biochemical or direct evidence for the existence of this oligomeric state.  
302 To assess the dynamics of both complexes in the presence or absence of O<sub>2</sub>, we performed  
303 molecular dynamics (MD) simulations of four complexes: HigB<sub>2</sub>HigA<sub>2</sub> and HigBHigA<sub>2</sub> in the  
304 presence or absence of O<sub>2</sub> (**Fig. 6**). The trimeric HigBHigA<sub>2</sub> complex in the absence of DNA  
305 has not been solved and we generated the model based upon the HigBHigA<sub>2</sub>-O<sub>2</sub> structure.  
306 We obtained 1 microsecond-long MD trajectories of each complex and subsequently  
307 performed root mean square fluctuation (RMSF) analysis. This analysis reveals overall  
308 comparable dynamics: in tetrameric HigB<sub>2</sub>HigA<sub>2</sub>, binding to O<sub>2</sub> only marginally affects  
309 dynamics, with the largest effects observed at intrinsically flexible regions such as the C  
310 termini of HigA monomers (residues 94-102) and loop 3 of HigB (residues 56-62) (**Fig. 6A**).  
311 In trimeric HigBHigA<sub>2</sub>, similar trends are observed, confirming that both oligomeric states  
312 represent similarly stable, DNA-bound complexes (**Fig. 6B**). One noted difference is that in  
313 the trimeric HigBHigA<sub>2</sub>-O<sub>2</sub> complex, the C-termini of one of the two HigAs is disordered and  
314 is not modeled. Two HigB monomers binding causes the C-termini of HigA to regain order  
315 but while the C-termini of both HigA monomers can be modeled, this region still exhibits  
316 dynamic behavior.

317  
318 **Engineered trimeric HigBHigA<sub>2</sub> transcriptionally represses *Phig*.** To test whether a  
319 trimeric HigBHigA<sub>2</sub> complex represses transcription to the same extent as HigB<sub>2</sub>HigA<sub>2</sub>, we  
320 attempted to engineer such a variant. Comparison of the HigB<sub>2</sub>HigA<sub>2</sub> structure with the  
321 HigB<sub>2</sub>HigA<sub>2</sub>-O<sub>2</sub> DNA structure shows that the two HigB monomers move closer to each other  
322 to accommodate binding to DNA (**Fig. 7A**). In particular, HigB loop 5 (L5) located at the  
323 interface of the HigB monomers moves ~4Å (**Fig. 4D**). We therefore extended L5 by the

324 addition of a short, flexible sequence of four residues (Asn, Gly, Asn, Gly (NGNG)); called  
325 HigB(L5ext)HigA<sub>2</sub>) to prevent concurrent binding of two HigB monomers to HigA<sub>2</sub> (**Fig. 7A**).  
326 Expression and purification of HigB(L5ext)HigA<sub>2</sub> showed a delayed elution of the complex  
327 from the size exclusion column as compared to wild-type HigB<sub>2</sub>HigA<sub>2</sub> (**Fig. 7B**), at a volume  
328 corresponding to a molecular weight of 42 kDa (compared to 56 kDa for wild-type  
329 HigB<sub>2</sub>HigA<sub>2</sub>). The difference in apparent molecular weights indicates that the  
330 HigB(L5ext)HigA<sub>2</sub> complex is ~14 kDa smaller than the wild-type complex which roughly  
331 corresponds to a HigB monomer (molecular weight of ~13 kDa). To assess its thermal  
332 stability, we performed nano-differential scanning fluorimetry (nano-DSF) which provides  
333 information on the melting temperature ( $T_m$ ) of the complex. Since this measurement is not  
334 at equilibrium, the inflection point is known as  $T_i$ . HigB(L5ext)HigA<sub>2</sub> is ~5°C less thermostable  
335 than wild-type HigB<sub>2</sub>HigA<sub>2</sub> (60.5°C vs. 54.0°C) consistent with an altered oligomeric state  
336 (**Fig. 7C**).

337 To test the ability of the HigB(L5ext)HigA<sub>2</sub> variant to repress transcription at *hig*, we  
338 performed EMSA and  $\beta$ -gal assays using similar approaches as described above. The  
339 HigB(L5ext)HigA<sub>2</sub> complex binds to both O1 and O2 DNAs at concentrations similar to wild-  
340 type HigB<sub>2</sub>HigA<sub>2</sub> (**Fig. 8A**). Although an intermediate shift is observed (likely representing a  
341 HigA<sub>2</sub> dimer bound), these data show the trimeric HigB(L5ext)HigA<sub>2</sub> interacts with O1 and  
342 O2 in a similar manner as wild-type HigB<sub>2</sub>HigA<sub>2</sub>. To determine whether the HigB(L5ext)HigA<sub>2</sub>  
343 complex represses *Phig in vivo*, we used the previously described *Phig* constructs and  
344 included a *Phig* containing the HigB(L5ext)HigA<sub>2</sub> variant (pQF50-*Phig-higB(L5ext)higA-lacZ*;  
345 **Fig. 8B**; **Fig. S7**). As expected, *Phig* alone shows high  $\beta$ -gal activity (normalize to 0%  
346 repression) because of the absence of transcriptional repressor HigA. *Phig-higBhigA-lacZ*  
347 shows little  $\beta$ -gal activity indicating robust HigA repression at *Phig* (~95% repression). The

348 HigB(L5ext)HigA<sub>2</sub> variant shows similar repression as wild-type HigB<sub>2</sub>HigA<sub>2</sub> suggesting  
349 there is no difference between a trimeric or tetrameric HigBHigA complex.

350 One possibility that we wanted to explore was whether *hig* is responsive to changing  
351 toxin levels *in vivo* considering that toxin overexpression in the *phddoc*, *ccdBccdA* and *relEB*  
352 systems can relieve repression (17, 18, 27). For this assay, we used a HigB variant (H54A)  
353 that is not catalytically active so cell growth won't be impacted by its expression and we  
354 know this variant is expressed as detected by Western blot analysis (34, 43). Further, since  
355 the active site of HigB is on the opposite surface from its HigA binding surface (26), this  
356 variant should not interfere with HigA binding. Overexpression of HigB(H54A) showed  
357 minimal impact on repression of *Phig-higBhigA* indicating free HigB(H54A) is unable to  
358 interact with HigB<sub>2</sub>HigA<sub>2</sub> bound at O1 or O2 (97.2% vs. 98.0%; **Fig. 8B**). In the case of the  
359 engineered HigB(L5ext)HigA<sub>2</sub>, excess HigB(H54A) expression also has no effect on  
360 repression and does not interfere with HigA-mediated repression (**Fig. 8B**). These data  
361 support a model whereby *hig* repression is only relieved by HigA proteolysis.

362

## 363 **DISCUSSION**

364 The roles of bacterial TA modules have been controversial owing to experimental errors in  
365 the construction of *E. coli* TA deletion strains and the ambiguity over what activates toxin  
366 expression, antitoxin proteolysis and the release of toxin (10, 44, 45). While these activities  
367 are still under debate, the way these modules are transcriptionally autoregulated is known  
368 to clearly contribute to their changing expression patterns in response to external stimuli  
369 although many outstanding questions still remain (17, 18, 27). One question is how different  
370 oligomeric TA complexes influence physical interactions with their DNA operators and the  
371 assembly and/ or cooperativity of TA complexes bound at adjacent operator sites. In this  
372 study, we focused on the regulation of the *higBhigA* TA module first identified on the

373 antibiotic-resistance Rts1 plasmid associated with a urinary tract infection caused by *P.*  
374 *vulgaris* (32). Our prior work revealed that while the HigB toxin adopts a canonical  
375 ribonuclease fold similar to other members of the RelE family (26), HigA antitoxin suppresses  
376 HigB activity in an unusual manner, suggesting that transcriptional repression may also be  
377 different. We therefore sought to understand how the *higBhigA* operon is regulated and how  
378 its diverse architecture might influence its negative regulation of transcription.

379 Higher-order oligomeric complexes of the PhDDoc, RelBRelE and CcdBCcdA TA  
380 complexes alter their thermodynamic interactions with operators and thus influence  
381 transcriptional responsiveness (17, 18, 27). We find that although HigA binding at adjacent  
382 operators is not cooperative (38) (**Fig. 2**), the addition of HigB promotes the formation of  
383 higher-order complexes and disassembly of the complex does appear to occur once a  
384 threshold of excess toxin to antitoxin is reached (**Figs. 2,3**). On the surface, these data  
385 appear to be consistent with how other TAs are regulated via the conditional cooperativity  
386 model or, as other transcriptional systems are described, as molecular rheostats (14).  
387 However, in an attempt to perturb the system *in vivo* by increasing HigB concentrations in  
388 the presence of the HigBHigA complex bound at O1 and O2 operators, we find no observable  
389 change in repression in contrast to these TA systems (**Fig. 8B**). These conflicting data  
390 indicate that the perceived disruption of the higher order HigBHigA-O2 DNA complex via  
391 EMSA may not be reflective of transcriptional repression that we observe *in vivo*. Further,  
392 these results suggest a different mode of regulation for the *higBhigA* operon.

393 One hallmark of conditional cooperativity that defines transcriptional regulation of TA  
394 operons is that the addition of excess toxin to antitoxins bound at operator sites changes the  
395 affinity of these interactions because toxin can act both as a co-repressor and de-repressor  
396 (17, 18, 22). In general, when the toxin and antitoxin are expressed at equimolar ratios, the  
397 toxin functions as a co-repressor and transcriptional repression is enhanced. Once toxin



398 concentrations exceed that of the antitoxin, however, disruption of the repressor complex  
399 ensues, antitoxin disengages from the promoter, and transcription proceeds (**Fig. 1**). To  
400 achieve this mode of regulation, defined oligomeric states of TA complexes have different  
401 affinities: for example, although the structure of RelBRelE complex indicates the complex is  
402 tetrameric with two RelE toxins and two RelB antitoxins (21), a trimeric version of the  
403 complex (two RelBs, one RelE) is proposed to have the highest affinity for the *rel* operon  
404 (18, 21). In the presence of a greater excess of toxin, the tetrameric RelB<sub>2</sub>RelE<sub>2</sub> forms at  
405 adjacent operators causing a change from a high affinity to a low affinity state, and the  
406 RelBRelE complex no longer binds to DNA (**Fig. 1**). This model permits the system to be  
407 responsive to changing levels of toxin but at this point, there is limited biochemical and  
408 structural data that corresponds to these changing oligomeric states.

409 We serendipitously solved two different structures of the HigBHigA-O<sub>2</sub> complexes  
410 that differ in their molar ratios of HigA antitoxin to the HigB toxin (**Figs. 4,5**). These different  
411 oligomeric states capture, for the first time, how both the tetrameric HigB<sub>2</sub>HigA<sub>2</sub> and trimeric  
412 HigBHigA<sub>2</sub> interact with O<sub>2</sub> to repress transcription. The trimeric HigBHigA<sub>2</sub>-O<sub>2</sub> DNA  
413 structure was especially unexpected given that the tetrameric HigB<sub>2</sub>HigA<sub>2</sub> form predominates  
414 in the absence of operator (26). The molecular interactions of each HigBHigA complex with  
415 its operator are largely maintained, initially suggesting that different oligomeric states may  
416 not contribute to changes in repression for this system. Molecular dynamic simulations of  
417 both the trimeric and tetrameric HigBHigA-O<sub>2</sub> complexes show each complex have similar  
418 dynamics when bound to DNA, offering further support for the ability of both oligomeric states  
419 to contribute to repression (**Fig. 6**). Further, engineering of a forced trimeric HigBHigA<sub>2</sub>  
420 oligomeric complex revealed similar levels of transcriptional repression (**Figs. 7,8; Fig. S7**).  
421 Together, these data support a model where *hig* is regulated as a simple on/off switch

422 incalitrant to changing levels of toxin and influenced solely by HigA proteolysis likely as  
423 result of the Rts1 plasmid not being inherited.

424         There are several other reasons for why *hig* may be regulated in a different manner  
425 from other TA operons. In TA operons regulated as molecular rheostats including *phddoc*,  
426 *relBreIE* and *ccdBccdA*, a single promoter controls expression of the operon and the  
427 antitoxin is encoded first (17, 18, 22). It has been suggested this operon organization allows  
428 for the antitoxin to be expressed in excess of the toxin, which is required to suppress toxicity  
429 when the system is transcriptionally de-repressed (46, 47). In *hig*, there is a second weak  
430 promoter, *PhigA*, that allows for independent expression of HigA to ensure excess HigA is  
431 always present to suppress HigB (48). It is not clear if this change in operon organization  
432 accounts for why *hig* is regulated via a simple on/off switch but other TA operons such as  
433 *mqsRA* that also have this reverse architecture and contain multiple promoters do not appear  
434 to be regulated via conditional cooperativity (29). In contrast, the DinJ-YafQ TA module does  
435 not have this reverse architecture but does not appear to be regulated by conditional  
436 cooperativity (30). Therefore, there must be some other currently unappreciated mechanism  
437 by which this TA system balances antitoxin expression for its regulation.

438         The results presented here provide new insight into the transcriptional regulation of  
439 the plasmid-associated *hig* operon and add to the growing diversity of mechanisms used to  
440 balance transcriptional responses of these abundant bacterial gene pairs. In the future,  
441 additional biophysical studies are needed to reconcile the role of changing macromolecular  
442 complex formation in the regulation of TA pairs and to align these properties with  
443 transcriptional responsiveness.

444

445 **MATERIALS AND METHODS**

446 **Strains and plasmids.** *E. coli* BL21(DE3) cells were used for expression of His<sub>6</sub>-HigA, His<sub>6</sub>-  
447 HigBHigA and HigBHigA-His<sub>6</sub> proteins from pET28a, pET28a and pET21c vectors,  
448 respectively as previously reported (26). *E. coli* BW25113 cells were used for all  $\beta$ -gal  
449 experiments and HigB(H54A)-His<sub>6</sub> expression (49). All point mutations were introduced by  
450 site-directed mutagenesis and sequences were verified by DNA sequencing (Genewiz).

451  
452 **HigA, HigB and HigBHigA expression and purification.** The His<sub>6</sub>-HigA, His<sub>6</sub>-HigBHigA  
453 and HigBHigA-His<sub>6</sub> protein complexes were overexpressed and purified as previously  
454 described with minor modifications (26). These differences included incubation of His<sub>6</sub>-HigA  
455 at 18°C overnight after protein induction and removal of the His<sub>6</sub> tag from His<sub>6</sub>-HigA and His<sub>6</sub>-  
456 HigBHigA with thrombin prior to gel filtration chromatography. HigB(H54A) protein was  
457 overexpressed and purified as previously described (43).

458  
459 **Electrophoretic mobility shift assays (EMSAs).** To construct the dsDNA for the EMSA,  
460 pairs of complementary single-stranded oligonucleotides were diluted to 2  $\mu$ M each in 100  
461 mM NaCl, 10 mM Tris-HCl pH8. The O1-O2, O1-O2(scrambled) or O1(scrambled)-O2  
462 oligonucleotide mixtures (**Table S1**) of the *hig* promoter fragment were incubated in boiling  
463 water and then cooled at room temperature overnight. The dsDNA oligos were diluted to 150  
464 nM in EMSA binding buffer (100 mM NaCl, 10 mM MgCl<sub>2</sub>, 5% glycerol, 0.01 mg/mL bovine  
465 serum albumin). Purified wild-type HigA, HigBHigA, and HigB(L5ext)HigA proteins were  
466 diluted to 10  $\mu$ M in EMSA binding buffer and serially diluted to give a series of protein  
467 concentrations ranging from 25 nM to 0.8  $\mu$ M. The binding reactions were incubated on ice  
468 for 20 min and 10  $\mu$ L of each reaction was loaded onto 8% native, polyacrylamide-0.5X  
469 TBE/10% glycerol gels (50 mM Tris-HCl pH 8, 50 mM boric acid, 5 mM EDTA, 10% glycerol)  
470 and subjected to electrophoresis at 110 V limiting on ice for 60 min. To visualize the DNA

471 and DNA-protein complexes, the gels were stained with SYBR green nucleic acid gel stain  
472 (ThermoFisher Scientific) in 0.5X TBE/10% glycerol for 30 min with gentle agitation and then  
473 the fluorescence was imaged with a Typhoon Trio phosphoimager (GE Healthcare; 488 nm  
474 excitation and 526 nm emission). Assays were performed in duplicate with representative  
475 gels shown. Band intensities for both free and bound *hig* DNA were quantified with  
476 ImageQuant 1D gel analysis software using the rolling ball background subtraction. For HigA  
477 or HigBHigA bound to either O1 or O2, the binding data were fit using a one site-specific  
478 binding equation ( $Y$  (specific binding,  $\mu\text{M}$ ) =  $B_{\text{max}} * X / [K_D + X]$ ) in GraphPad Prism 9.0.0.

479  
480 **Crystallization, data collection and structure determination of the HigBHigA-O2 DNA**  
481 **complexes.** The complex was formed by mixing either His<sub>6</sub>-HigBHigA or selenomethionine-  
482 derivatized HigBHigA-His<sub>6</sub> (both in 40 mM Tris-HCl, pH 7.5, 250 mM KCl, 5 mM MgCl<sub>2</sub>, and  
483 5 mM  $\beta$ -mercaptoethanol) with O2 operator DNA (10 mM Tris, pH 8, 100 mM NaCl, and 1  
484 mM EDTA) at one HigB<sub>2</sub>HigA<sub>2</sub> tetramer to one O2 dsDNA molar ratio. The complexes were  
485 diluted to 5.95 mg/mL HigBHigA and 1.55 mg/mL O2 DNA by the addition of buffer (20 mM  
486 Tris, pH 8, 10 mM MgCl<sub>2</sub>, and 100 mM NaCl). Crystals of HigBHigA bound to O2 DNA were  
487 grown by sitting drop vapor diffusion and crystallized in 0.2 M CaCl<sub>2</sub> and 10-25% (w/v)  
488 polyethylene glycol 3,350 at 20°C. Both crystal forms grew after two days and were  
489 cryoprotected by serially increasing the concentration of ethylene glycol in the mother liquor  
490 from 10-30% (w/v) followed by flash freezing in liquid nitrogen.

491 Two X-ray datasets were collected at the Northeastern Collaborative Access Team  
492 (NE-CAT) 24-ID-C and Southeast Regional Collaborative Access Team (SER-CAT) 22-ID  
493 facilities at the Advanced Photon Source (APS) at the Argonne National Laboratory. For the  
494 tetrameric HigB<sub>2</sub>HigA<sub>2</sub>-O2 complex, 360° of data (0.5° oscillations) were collected on a  
495 PILATUS 6M-F detector (DECTRIS Ltd., Switzerland) using 0.9792 Å radiation. For the

496 trimeric HigBHigA<sub>2</sub>-O<sub>2</sub> complex, 90° of data (0.5° oscillations) were collected on a  
497 MARMOSAIC 300 mm CCD detector (Rayonix, L.L.C., USA) using 1.0 Å radiation. XDS was  
498 used to integrate and scale the data (50). The tetrameric HigB<sub>2</sub>HigA<sub>2</sub>-O<sub>2</sub> structure was  
499 solved by single wavelength anomalous diffraction phasing using AutoSol from the PHENIX  
500 software suite (51) and thirteen heavy atom sites were found. The trimeric HigBHigA<sub>2</sub>-O<sub>2</sub>  
501 structure was solved using the structure of the HigA<sub>2</sub> dimer (PDB code 6CF1) as a molecular  
502 replacement search model in the PHENIX software suite. XYZ coordinates, real space, and  
503 B-factors (isotropic) were refined iteratively in PHENIX and model building was performed  
504 using the program Coot (52). Final refinement of the structures gave crystallographic  
505 R<sub>work</sub>/R<sub>free</sub> of 17.6/21.8% for trimeric HigBHigA<sub>2</sub>-O<sub>2</sub> and 17.5/22.1% for tetrameric  
506 HigB<sub>2</sub>HigA<sub>2</sub>-O<sub>2</sub>. All figures were created in PyMol (53).

507  
508 **β-galactosidase assays.** The *hig* operon was chemically synthesized (IDT), digested and  
509 ligated into a pQF50 vector with *lacZ* downstream (pQF50-*hig* constructs). *E. coli* BW25113  
510 transformed with pQF50-*hig* variants or pBAD33-*higB*(H54A) were used for all experiments.  
511 Two methods were used to perform β-gal assays. The first set of β-gal assays presented  
512 herein (with constructs containing wild-type versus mutated operators) were performed using  
513 the PopCulture® Reagent based method (54). All overnight cultures were grown in M9  
514 minimal media supplemented with 0.2% glucose, 1 M MgSO<sub>4</sub>, 1 M CaCl<sub>2</sub>, and 10% casamino  
515 acids. Subsequent experiments were performed with M9 minimal media supplemented with  
516 20% glycerol instead of glucose. OD<sub>600</sub> was measured hourly until an OD<sub>600</sub> of 0.2 was  
517 reached, arabinose was added to a final concentration of 0.2%, and further incubated for 4  
518 hrs. 1 mL aliquots were pelleted, resuspended in 500 μL of M9 media and diluted to an OD<sub>600</sub>  
519 of 0.5 in M9 media. 80 μL were transferred to 96-well plate and 120 μL of freshly mixed β-  
520 gal reagent (60 mM Na<sub>2</sub>SO<sub>4</sub>, 40 mM NaH<sub>2</sub>PO<sub>4</sub>, 10 mM KCl, 1 mM MgSO<sub>4</sub>, 36 mM β-me, 166

521  $\mu\text{L}/\text{mL}$  T7 lysozyme, 1.1 mg/mL ortho-Nitrophenyl- $\beta$ -galactoside and 6.7% PopCulture®  
522 Reagent (Millipore-Sigma)) was added to each well. 80  $\mu\text{L}$  of M9 media was also added to  
523 wells containing 120  $\mu\text{L}$  of  $\beta$ -gal reagent as a negative control. The microplate was read by  
524 a Biotek Cytation 5 multi-mode reader pre-incubated at 30°C, with  $\text{OD}_{600}$  and  $\text{OD}_{420}$   
525 measurements taken every 5 min for 1 hr with agitation.

526 The second set of  $\beta$ -gal assays presented herein (in the absence or presence of  
527 HigB(H54A)) were performed using a method previously described (38). In both approaches,  
528 activity in Miller Units (M.U.) was measured using the formula: total activity (M.U.) =  
529  $(1000 \cdot \text{OD}_{420}) / (\text{OD}_{600} \cdot \text{volume of culture used (mL)} \cdot 0.5)$ . Assays were performed in  
530 triplicate with two technical replicates.

531  
532 **Differential scanning fluorimetry (DSF).** The thermal stability of wild-type HigBHigA and  
533 HigB(L5ext)HigA were assessed using a Tycho NT.6 instrument (NanoTemper). Protein was  
534 heated at 0.1°C steps over a temperature range of 35°C to 95°C, during which intrinsic  
535 fluorescence at 350 and 330 nm was measured. Inflection temperature ( $T_i$ ) was determined  
536 for each apparent unfolding transition from the temperature-dependent change in the ratio  
537 of 350 and 330 nm measurements. Assays were performed in triplicates.

538  
539 **Molecular dynamics simulations.** Starting models for molecular dynamics (MD)  
540 simulations were prepared from PDB codes 6W6U (HigB<sub>2</sub>HigA<sub>2</sub>-O2) and 6WFP (HigBHigA<sub>2</sub>-  
541 O2). Simulations were performed on the tetrameric or trimeric HigBHigA structures in the  
542 absence or presence of O2 DNA (HigB<sub>2</sub>HigA<sub>2</sub>-O2, HigBHigA<sub>2</sub>-O2, HigB<sub>2</sub>HigA<sub>2</sub> and  
543 HigBHigA<sub>2</sub>). All complexes were prepared using the Xleap module of AmberTools 18 (55),  
544 the ff14SB forcefield for protein atoms (56) and the OL15 forcefield (57) for DNA. Complexes  
545 were solvated in an octahedral box of TIP3P water (58) with a 10 Å buffer. Ions were added

546 to each complex to achieve a final concentration of 150 mM NaCl. Minimization was  
547 performed in three rounds, each employing steepest descent (5000 steps) followed by  
548 conjugate gradient (5000 steps). In the first round, restraints of 500 kcal/mol-Å<sup>2</sup> were applied  
549 to all solute atoms. In the second round, solute restraints were reduced to 100 kcal/mol-Å<sup>2</sup>.  
550 All restraints were removed in the third round. Complexes were heated from 0 to 300 K with  
551 a 100-ps run with constant volume periodic boundaries and restraints of 10-kcal/mol-Å<sup>2</sup> on  
552 solute atoms. All MD simulations were performed using AMBER2018 (55, 59, 60). Two  
553 stages of equilibration were performed: 10 ns MD in the NPT ensemble with 10-kcal/mol-Å<sup>2</sup>  
554 restraints on solute atoms, followed by an additional 10 ns MD run with restraints reduced  
555 to 1 kcal/mol-Å<sup>2</sup>. Finally all restraints were removed and 1 microsecond production  
556 simulations obtained for each complex. Long-range electrostatics were evaluated with a  
557 cutoff of 10 Å and all heavy atom-hydrogen bonds were fixed with the SHAKE algorithm (61).  
558 Following MD, the CPPTRAJ module (62) of AmberTools 18 was used to calculate root mean  
559 square fluctuations (RMSF) of each protein residue in each complex.

560

## 561 **ACKNOWLEDGEMENTS**

562 Research reported in this publication was partially supported by a National Science  
563 Foundation CAREER award MCB 0953714 (CMD), a NIH Biochemistry, Cellular and  
564 Molecular Biology Graduate Training Grant 5T32GM8367 (MAS), and NIH NRSA F31  
565 Fellowship GM108351 (MAS) and a Burroughs Wellcome Fund Investigator in the  
566 Pathogenesis of Infectious Disease award (CMD). We thank F. M. Murphy IV and staff  
567 members of the NE-CAT beamlines for assistance during data collection and G. L. Conn  
568 and other Dunham lab members for critical reading of the manuscript. This work is based  
569 upon research conducted at the Northeastern Collaborative Access Team beamlines, which  
570 are funded by the National Institute of General Medical Sciences from the National Institutes

571 of Health (P30 GM124165). Additional data were collected at the Southeast Regional  
572 Collaborative Access Team (SER-CAT) 22-ID (or 22-BM) beamline at the Advanced Photon  
573 Source, Argonne National Laboratory. SER-CAT is supported by its member institutions  
574 ([www.ser-cat.org/members.html](http://www.ser-cat.org/members.html)) and equipment grants (S10RR25528 and S10RR028976)  
575 from the National Institutes of Health. Use of the Advanced Photon Source was supported  
576 by the U. S. Department of Energy, Office of Science, Office of Basic Energy Sciences,  
577 under Contract No. DE-AC02-06CH11357.

578

## 579 REFERENCES

- 580 1. D. P. Pandey, K. Gerdes, Toxin-antitoxin loci are highly abundant in free-living but lost from  
581 host-associated prokaryotes. *Nucleic Acids Res* **33**, 966-976 (2005).
- 582 2. K. S. Makarova, Y. I. Wolf, E. V. Koonin, Comprehensive comparative-genomic analysis of  
583 type 2 toxin-antitoxin systems and related mobile stress response systems in prokaryotes.  
584 *Biol Direct* **4**, 19 (2009).
- 585 3. R. Leplae *et al.*, Diversity of bacterial type II toxin-antitoxin systems: a comprehensive search  
586 and functional analysis of novel families. *Nucleic Acids Res* **39**, 5513-5525 (2011).
- 587 4. H. Karoui, F. Bex, P. Dreze, M. Couturier, Ham22, a mini-F mutation which is lethal to host  
588 cell and promotes recA-dependent induction of lambdoid prophage. *EMBO J* **2**, 1863-1868  
589 (1983).
- 590 5. T. Ogura, S. Hiraga, Mini-F plasmid genes that couple host cell division to plasmid  
591 proliferation. *Proc Natl Acad Sci U S A* **80**, 4784-4788 (1983).
- 592 6. K. Gerdes, P. B. Rasmussen, S. Molin, Unique type of plasmid maintenance function:  
593 postsegregational killing of plasmid-free cells. *Proc Natl Acad Sci U S A* **83**, 3116-3120  
594 (1986).



- 595 7. A. Bravo, G. de Torrontegui, R. Diaz, Identification of components of a new stability system  
596 of plasmid R1, ParD, that is close to the origin of replication of this plasmid. *Mol Gen Genet*  
597 **210**, 101-110 (1987).
- 598 8. S. Tsuchimoto, H. Ohtsubo, E. Ohtsubo, Two genes, pemK and pemI, responsible for stable  
599 maintenance of resistance plasmid R100. *J Bacteriol* **170**, 1461-1466 (1988).
- 600 9. H. Lehnherr, E. Maguin, S. Jafri, M. B. Yarmolinsky, Plasmid addiction genes of  
601 bacteriophage P1: doc, which causes cell death on curing of prophage, and phd, which  
602 prevents host death when prophage is retained. *Journal of molecular biology* **233**, 414-428  
603 (1993).
- 604 10. N. Fraikin, F. Goormaghtigh, L. Van Melderen, Type II Toxin-Antitoxin Systems: Evolution  
605 and Revolutions. *J Bacteriol* **202** (2020).
- 606 11. R. Loris, A. Garcia-Pino, Disorder- and dynamics-based regulatory mechanisms in toxin-  
607 antitoxin modules. *Chemical reviews* **114**, 6933-6947 (2014).
- 608 12. R. Page, W. Peti, Toxin-antitoxin systems in bacterial growth arrest and persistence. *Nat*  
609 *Chem Biol* **12**, 208-214 (2016).
- 610 13. F. M. Rossi, A. M. Kringstein, A. Spicher, O. M. Guicherit, H. M. Blau, Transcriptional control:  
611 rheostat converted to on/off switch. *Mol Cell* **6**, 723-728 (2000).
- 612 14. E. Batchelor, T. J. Silhavy, M. Goulian, Continuous control in bacterial regulatory circuits. *J*  
613 *Bacteriol* **186**, 7618-7625 (2004).
- 614 15. M. Gotfredsen, K. Gerdes, The Escherichia coli relBE genes belong to a new toxin-antitoxin  
615 gene family. *Mol Microbiol* **29**, 1065-1076 (1998).
- 616 16. R. Magnuson, M. B. Yarmolinsky, Corepression of the P1 addiction operon by Phd and Doc.  
617 *J Bacteriol* **180**, 6342-6351 (1998).
- 618 17. H. Afif, N. Allali, M. Couturier, L. Van Melderen, The ratio between CcdA and CcdB modulates  
619 the transcriptional repression of the ccd poison-antidote system. *Mol Microbiol* **41**, 73-82  
620 (2001).

- 621 18. M. Overgaard, J. Borch, M. G. Jorgensen, K. Gerdes, Messenger RNA interferase RelE  
622 controls relBE transcription by conditional cooperativity. *Mol Microbiol* **69**, 841-857 (2008).
- 623 19. A. Harms, D. E. Brodersen, N. Mitarai, K. Gerdes, Toxins, Targets, and Triggers: An Overview  
624 of Toxin-Antitoxin Biology. *Mol Cell* **70**, 768-784 (2018).
- 625 20. T. Madl *et al.*, Structural basis for nucleic acid and toxin recognition of the bacterial antitoxin  
626 CcdA. *Journal of molecular biology* **364**, 170-185 (2006).
- 627 21. A. Boggild *et al.*, The crystal structure of the intact E. coli RelBE toxin-antitoxin complex  
628 provides the structural basis for conditional cooperativity. *Structure* **20**, 1641-1648 (2012).
- 629 22. A. Garcia-Pino *et al.*, Allosteric and intrinsic disorder mediate transcription regulation by  
630 conditional cooperativity. *Cell* **142**, 101-111 (2010).
- 631 23. C. Dienemann, A. Boggild, K. S. Winther, K. Gerdes, D. E. Brodersen, Crystal structure of  
632 the VapBC toxin-antitoxin complex from *Shigella flexneri* reveals a hetero-octameric DNA-  
633 binding assembly. *Journal of molecular biology* **414**, 713-722 (2011).
- 634 24. B. L. Brown *et al.*, Three dimensional structure of the MqsR:MqsA complex: a novel TA pair  
635 comprised of a toxin homologous to RelE and an antitoxin with unique properties. *PLoS*  
636 *Pathog* **5**, e1000706 (2009).
- 637 25. M. A. Schumacher *et al.*, Molecular mechanisms of HipA-mediated multidrug tolerance and  
638 its neutralization by HipB. *Science* **323**, 396-401 (2009).
- 639 26. M. A. Schureck *et al.*, Structure of the *Proteus vulgaris* HigB-(HigA)<sub>2</sub>-HigB toxin-antitoxin  
640 complex. *J Biol Chem* **289**, 1060-1070 (2014).
- 641 27. R. Magnuson, H. Lehnerr, G. Mukhopadhyay, M. B. Yarmolinsky, Autoregulation of the  
642 plasmid addiction operon of bacteriophage P1. *J Biol Chem* **271**, 18705-18710 (1996).
- 643 28. I. Brzozowska, U. Zielenkiewicz, Regulation of toxin-antitoxin systems by proteolysis. *Plasmid*  
644 **70**, 33-41 (2013).
- 645 29. B. L. Brown, D. M. Lord, S. Grigoriu, W. Peti, R. Page, The *Escherichia coli* toxin MqsR  
646 destabilizes the transcriptional repression complex formed between the antitoxin MqsA and  
647 the mqsRA operon promoter. *J Biol Chem* **288**, 1286-1294 (2013).

- 648 30. A. Ruangprasert *et al.*, Mechanisms of toxin inhibition and transcriptional repression by  
649 Escherichia coli DinJ-YafQ. *J Biol Chem* **289**, 20559-20569 (2014).
- 650 31. Y. Terawaki, H. Takayasu, T. Akiba, Thermosensitive replication of a kanamycin resistance  
651 factor. *J Bacteriol* **94**, 687-690 (1967).
- 652 32. Q. B. Tian, M. Ohnishi, A. Tabuchi, Y. Terawaki, A new plasmid-encoded proteic killer gene  
653 system: cloning, sequencing, and analyzing hig locus of plasmid Rts1. *Biochem Biophys Res*  
654 *Commun* **220**, 280-284 (1996).
- 655 33. J. M. Hurley, N. A. Woychik, Bacterial toxin HigB associates with ribosomes and mediates  
656 translation-dependent mRNA cleavage at A-rich sites. *J Biol Chem* **284**, 18605-18613 (2009).
- 657 34. M. A. Schureck, J. A. Dunkle, T. Maehigashi, S. J. Miles, C. M. Dunham, Defining the mRNA  
658 recognition signature of a bacterial toxin protein. *Proc Natl Acad Sci U S A* **112**, 13862-13867  
659 (2015).
- 660 35. M. A. Schureck, T. Maehigashi, S. J. Miles, J. Marquez, C. M. Dunham, mRNA bound to the  
661 30S subunit is a HigB toxin substrate. *RNA* **22**, 1261-1270 (2016).
- 662 36. S. Hadzi *et al.*, Ribosome-dependent Vibrio cholerae mRNAse HigB2 is regulated by a beta-  
663 strand sliding mechanism. *Nucleic Acids Res* **45**, 4972-4983 (2017).
- 664 37. B. S. Xu *et al.*, Conformational changes of antitoxin HigA from Escherichia coli str. K-12 upon  
665 binding of its cognate toxin HigB reveal a new regulation mechanism in toxin-antitoxin  
666 systems. *Biochem Biophys Res Commun* **514**, 37-43 (2019).
- 667 38. M. A. Schureck *et al.*, Structural basis of transcriptional regulation by the HigA antitoxin. *Mol*  
668 *Microbiol* **111**, 1449-1462 (2019).
- 669 39. Q. B. Tian *et al.*, Specific protein-DNA and protein-protein interaction in the hig gene system,  
670 a plasmid-borne proteic killer gene system of plasmid Rts1. *Plasmid* **45**, 63-74 (2001).
- 671 40. M. H. Dao-Thi *et al.*, Molecular basis of gyrase poisoning by the addiction toxin CcdB. *Journal*  
672 *of molecular biology* **348**, 1091-1102 (2005).

- 673 41. S. K. Khoo *et al.*, Molecular and structural characterization of the PezAT chromosomal toxin-  
674 antitoxin system of the human pathogen *Streptococcus pneumoniae*. *J Biol Chem* **282**,  
675 19606-19618 (2007).
- 676 42. M. Overgaard, J. Borch, K. Gerdes, RelB and RelE of *Escherichia coli* form a tight complex  
677 that represses transcription via the ribbon-helix-helix motif in RelB. *Journal of molecular*  
678 *biology* **394**, 183-196 (2009).
- 679 43. M. A. Schureck, A. Repack, S. J. Miles, J. Marquez, C. M. Dunham, Mechanism of  
680 endonuclease cleavage by the HigB toxin. *Nucleic Acids Res* **44**, 7944-7953 (2016).
- 681 44. A. Harms, C. Fino, M. A. Sorensen, S. Semsey, K. Gerdes, Prophages and Growth Dynamics  
682 Confound Experimental Results with Antibiotic-Tolerant Persister Cells. *mBio* **8** (2017).
- 683 45. F. Goormaghtigh *et al.*, Reassessing the Role of Type II Toxin-Antitoxin Systems in Formation  
684 of *Escherichia coli* Type II Persister Cells. *mBio* **9** (2018).
- 685 46. W. T. Chan, M. Espinosa, C. C. Yeo, Keeping the Wolves at Bay: Antitoxins of Prokaryotic  
686 Type II Toxin-Antitoxin Systems. *Front Mol Biosci* **3**, 9 (2016).
- 687 47. H. S. Deter, R. V. Jensen, W. H. Mather, N. C. Butzin, Mechanisms for Differential Protein  
688 Production in Toxin-Antitoxin Systems. *Toxins* **9** (2017).
- 689 48. Q. B. Tian, T. Hayashi, T. Murata, Y. Terawaki, Gene product identification and promoter  
690 analysis of hig locus of plasmid Rts1. *Biochem Biophys Res Commun* **225**, 679-684 (1996).
- 691 49. K. A. Datsenko, B. L. Wanner, One-step inactivation of chromosomal genes in *Escherichia*  
692 *coli* K-12 using PCR products. *Proc Natl Acad Sci U S A* **97**, 6640-6645 (2000).
- 693 50. W. Kabsch, Xds. *Acta crystallographica* **66**, 125-132 (2010).
- 694 51. P. D. Adams *et al.*, PHENIX: a comprehensive Python-based system for macromolecular  
695 structure solution. *Acta crystallographica* **66**, 213-221 (2010).
- 696 52. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. *Acta*  
697 *crystallographica* **66**, 486-501 (2010).
- 698 53. Schrodinger, LLC (2010) The PyMOL Molecular Graphics System, Version 1.3r1.

- 699 54. J. Schaefer, G. Jovanovic, I. Kotta-Loizou, M. Buck, Single-step method for beta-  
700 galactosidase assays in Escherichia coli using a 96-well microplate reader. *Anal Biochem*  
701 **503**, 56-57 (2016).
- 702 55. I. Y. B.-S. D.A. Case, S.R. Brozell, D.S. Cerutti, T.E. Cheatham, III, V.W.D. Cruzeiro, T.A.  
703 Darden, R.E. Duke, D. Ghoreishi, M.K. Gilson, H. Gohlke, A.W. Goetz, D. Greene, R Harris,  
704 N. Homeyer, Y. Huang, S. Izadi, A. Kovalenko, T. Kurtzman, T.S. Lee, S. LeGrand, P. Li, C.  
705 Lin, J. Liu, T. Luchko, R. Luo, D.J. Mermelstein, K.M. Merz, Y. Miao, G. Monard, C. Nguyen,  
706 H. Nguyen, I. Omelyan, A. Onufriev, F. Pan, R. Qi, D.R. Roe, A. Roitberg, C. Sagui, S. Schott-  
707 Verdugo, J. Shen, C.L. Simmerling, J. Smith, R. SalomonFerrer, J. Swails, R.C. Walker, J.  
708 Wang, H. Wei, R.M. Wolf, X. Wu, L. Xiao, D.M. York and P.A. Kollman (2018) AMBER 2018.  
709 (University of California, San Francisco).
- 710 56. J. A. Maier *et al.*, ff14SB: Improving the Accuracy of Protein Side Chain and Backbone  
711 Parameters from ff99SB. *J Chem Theory Comput* **11**, 3696-3713 (2015).
- 712 57. R. Galindo-Murillo *et al.*, Assessing the Current State of Amber Force Field Modifications for  
713 DNA. *J Chem Theory Comput* **12**, 4114-4127 (2016).
- 714 58. W. L. Jorgensen, J. Chandrasekhar, J. D. Madura, R. W. Impey, M. L. Klein, Comparison of  
715 simple potential functions for simulating liquid water. *J. Chem. Phys.* **79** (1983).
- 716 59. R. Salomon-Ferrer, A. W. Gotz, D. Poole, S. Le Grand, R. C. Walker, Routine Microsecond  
717 Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh  
718 Ewald. *J Chem Theory Comput* **9**, 3878-3888 (2013).
- 719 60. S. Le Grand, A. W. Gotz, R. C. Walker, SPFP: Speed without compromise—A mixed  
720 precision model for GPU accelerated molecular dynamics simulations. *Computer Physics*  
721 *Communications* **184**, 374-380 (2013).
- 722 61. J. C. Ryckaert, G.; Berendsen, H.J.C., Numerical integration of the cartesian equations of  
723 motion of a system with constraints: molecular dynamics of n-alkanes. *Journal of*  
724 *Computational Physics* **23**, 327-341 (1977).

725 62. D. R. Roe, T. E. Cheatham, 3rd, PTRAJ and CPPTRAJ: Software for Processing and Analysis  
726 of Molecular Dynamics Trajectory Data. *J Chem Theory Comput* **9**, 3084-3095 (2013).

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745


746

747

748

749

750 **FIGURES**



751

752 **Figure 1. Diverse transcriptional control mechanisms that regulate expression of**

753 **toxin-antitoxin complexes.** Toxin (T) and antitoxin (A) proteins form multimeric complexes

754 that bind operator sites (O1 and O2) that overlap with their promoters (P<sub>TA</sub>) to repress

755 transcription. **(A)** In some type II toxin-antitoxin systems, changing levels of toxins (due to

756 antitoxin proteolysis) that bind to the repressor complex leads to steric clashes and/or

757 changes in affinity causing de-repression. In this case, the system functions as a molecular


758 rheostat responsive to toxin levels. **(B)** In contrast, other toxin-antitoxin systems are not

759 sensitive to changes in toxin concentrations and thus function as on/off transcriptional

760 switches dependent on antitoxin depletion from proteolysis.

761

762



763  
 764 **Figure 2. Binding of HigB<sub>2</sub>HigA<sub>2</sub> to a single operator is sufficient for transcriptional**  
 765 **repression of the *hig* operon. (A) Left, organization of the *hig* operon containing the**  
 766 **operators O1 and O2, the *Phig* promoter, *higB* toxin and *higA* antitoxin genes. Right, the**  
 767 **nucleotide sequences of O1 and O2, with the +1 transcriptional start site and the -35 and -**  
 768 **10 sites indicated. The sequence recognized by HigA is shown in grey and operator**  
 769 **nucleotides C<sub>-30</sub>, G<sub>-24</sub>, G<sub>-8</sub>, and C<sub>-2</sub> important for HigA binding are shown in bold. (B) EMSA**  
 770 **of HigB<sub>2</sub>HigA<sub>2</sub> binding to wild-type *Phig* (top), O1 only (O2 scrambled; middle), and O2 only**  
 771 **(O1 scrambled; bottom) DNA. Band intensities were plotted from EMSAs as the percent of**  
 772 **HigB<sub>2</sub>HigA<sub>2</sub> bound to DNA versus HigB<sub>2</sub>HigA<sub>2</sub> (concentrations used: 0, 0.025, 0.05, 0.1, 0.2,**  
 773 **0.3, 0.4, 0.5, 0.6, 0.7, 0.8 μM). Curves represent the fit from which K<sub>D</sub>s were calculated. (C)**  
 774 **β-gal assays of *E. coli* BW25113 transformed with pQF50-*Phig-lacZ* (black), pQF50-*Phig-***



775 *higA-lacZ* (dark grey), or pQF50-*Phig-higA*( $\Delta$ 84-104)-*lacZ* (light grey). Each operator site  
776 was tested using known operator mutations of either O1 (G<sub>-24</sub>T, C<sub>-30</sub>A) or O2 (G<sub>-7</sub>T, C<sub>-2</sub>A)  
777 (38).

778

779

780

781

782

783

784

785

786

787

788

789

790

791

792

793

794


795

796

797

798

799



800  
 801 **Figure 3. Formation of higher oligomeric states upon addition of HigB to the HigA-**  
 802 **DNA complex.** (A) EMSA of HigB addition to the HigA<sub>2</sub>-O1-O2 DNA complex. The O1-O2  
 803 DNA migrates the fastest (lane 1, black arrowhead) and incubation with the 0.5 μM HigA<sub>2</sub>  
 804 dimer results in a retardation of O1-O2 to form two shifts (lane 2, yellow and orange  
 805 arrowheads). Increasing amounts of HigB results in the formation of higher molecular weight  
 806 complexes (lanes 3-6, red and purple arrowheads). When the molar ratio of HigB to HigA  
 807 exceeds 1 (>1.0 μM HigB for 0.5 μM HigA<sub>2</sub> dimer), the high molecular weight shifts are no  
 808 longer observed indicating that neither HigA nor HigB binds. (B) Schematic of the different

809 HigBHigA-O1-O2 DNA complexes formed with changing the HigB:HigA ratio. Multiple  
810 oligomeric arrangements are possible in the case of a trimeric HigA<sub>2</sub>HigB complex but only  
811 one example is shown. (C) EMSA of HigB addition to the HigA<sub>2</sub>-O1-O2 DNA complex when  
812 either O1 or O2 is scrambled. O1-O2 DNA migrates the fastest (lane 1, black arrowhead)  
813 and incubation with the HigA<sub>2</sub> dimer results in a retardation of O1-O2 to form two shifts (lane  
814 2, orange arrowhead). The addition of HigB results in the formation of higher molecular  
815 weight complexes (lane 3, purple arrowhead) with a molar excess of HigB over HigA causes  
816 the scrambled DNA probe to be released (lane 5).

817

818

819

820

821

822

823

824

825

826

827

828


829

830

831

832

833



834

835 **Figure 4. Structure of tetrameric HigB<sub>2</sub>HigA<sub>2</sub> bound to O<sub>2</sub> DNA.** (A) The 2.4-Å structure

836 of tetrameric HigB<sub>2</sub>HigA<sub>2</sub>-O<sub>2</sub> DNA complex (PDB code 6W6U). HigA recognizes the T<sub>-1</sub>, G<sub>-2</sub>,

837 T<sub>-3</sub>, A<sub>-4</sub> DNA operator region via α<sub>2</sub> and α<sub>3</sub>. N and C-terminal regions of HigA are boxed. (B)

838 HigA Arg40 makes the only sequence specific interactions with the nucleobase of G<sub>-2</sub> while

839 HigA residues Thr34 and Thr37 (both from α<sub>3</sub>) stably interact with the phosphate of G<sub>-2</sub>. (C)

840 The N- and C-terminal residues of HigA become ordered upon both HigB binding. HigA


841 residue Arg77 forms a hydrogen bond with the backbone carbonyl of Gln3 and Arg2 and

842 Glu80 interact via a salt bridge. (D) Comparison of the tetrameric HigB<sub>2</sub>HigA<sub>2</sub> complex (all

843 black; PDB code 4MCX) and HigB<sub>2</sub>HigA<sub>2</sub>-O<sub>2</sub> DNA complex (PDB code 4MCX) reveal a ~14°

844 rotation of HigB<sub>2</sub>HigA<sub>2</sub> away from DNA that allows recognition.

845



846

847 **Figure 5. Structure of trimeric HigBHigA<sub>2</sub> bound to O<sub>2</sub> DNA.** The 2.8-Å structure of  
848 trimeric HigBHigA<sub>2</sub>-O<sub>2</sub> DNA (PDB code 6WFP). HigA recognizes the T<sub>+6</sub>, G<sub>+7</sub>, T<sub>+8</sub>, A<sub>+9</sub> DNA  
849 region via α<sub>2</sub> and α<sub>3</sub>. N and C-terminal regions of HigA are boxed. **(B)** In the HigB<sub>2</sub>HigA<sub>2</sub>-  
850 O<sub>2</sub> DNA structure (PDB code 6W6U), HigA residues Ser23, Ser39, and Lys45 interact with  
851 the backbone phosphate of T<sub>-7</sub>, T<sub>-5</sub>, and T<sub>-4</sub> respectively to rigidify the T<sub>-1</sub>, G<sub>-2</sub>, T<sub>-3</sub>, A<sub>-4</sub>  
852 sequence for nucleotide-specific recognition on the opposite strand. In the trimeric  
853 HigBHigA<sub>2</sub>-O<sub>2</sub> structure, only Ser39 interacts with the phosphate backbone and Ser23 and  
854 Lys45 are too distant (red highlighted region). **(C)** The N- and C-terminal residues of HigA  
855 become ordered upon a single HigB monomer binding similar to when two HigB monomers  
856 bind (Fig. 4C). **(D)** Comparison of trimeric HigBHigA<sub>2</sub>-O<sub>2</sub> DNA (pink; PDB code 6WFP) and

857 tetrameric HigB<sub>2</sub>HigA<sub>2</sub>-O<sub>2</sub> DNA (PDB code 6W6U) are incredibly similar with an r.m.s.d of  
858 0.7 Å (for 1479 equivalent atoms) and less than a ~1° rotation.

859

860

861

862

863

864

865

866

867

868

869

870

871

872

873

874

875

876


877

878

879

880

881



882

883 **Figure 6. Trimeric HigBHigA<sub>2</sub> and tetrameric HigB<sub>2</sub>HigA<sub>2</sub> exhibit similar dynamics in**

884 **the presence or absence of O<sub>2</sub> DNA.** Root-mean-square-fluctuations (RMSFs) of C $\alpha$

885 atoms for each residue in the (A) HigBHigA<sub>2</sub> or (B) HigB<sub>2</sub>HigA<sub>2</sub> complexes are calculated


886 from 1 ms MD trajectories. Regions that have increased RMSFs are indicated with

887 highlighted bars that correspond to their positions on the HigBHigA-O<sub>2</sub> structures (*right*).

888 High RMSF spikes correlate to either labile C-termini of HigA or HigB loop regions with

889 colored circles corresponding to the highlighted bars on the left.

890



891

892 **Figure 7. Engineering a trimeric HigBHigA<sub>2</sub> complex.** (A) To prevent two HigB monomers  
893 from binding, loop 5 (L5) of HigB was extended by the insertion of four residues (Asn, Gly,  
894 Asn, Gly; NGNG; “L5ext”, magenta) after residue Asp82. The dotted box indicating the L5  
895 region of two HigB monomers is zoomed in (right). The theoretical extension of L5 is shown  
896 in magenta with the wild-type HigB and HigB(L5ext) amino acid alignment shown  
897 underneath. (B) Size exclusion chromatography of purified wild-type HigB<sub>2</sub>HigA<sub>2</sub> shows an  
898 elution volume that corresponds to a molecular weight of 52 kDa. HigB(L5ext)HigA<sub>2</sub> complex  
899 (magenta) elutes at a volume corresponding to a molecular weight of 42 kDa with the inset  
900 showing a zoomed in view. Molecular weight standards are shown in grey. (C) Nano-DSF  
901 analysis of wild-type HigB<sub>2</sub>HigA<sub>2</sub> (black) and HigB(L5ext)HigA<sub>2</sub> (magenta) shows that the  
902 HigB(L5ext)HigA<sub>2</sub> complex has ~5°C lower T<sub>i</sub> value than HigB<sub>2</sub>HigA<sub>2</sub>. Fluorescence values



903 were normalized to the highest tested temperature and the boundary of each line represents  
904 the mean  $\pm$  SD of values of three independent experiments.

905

906

907

908

909

910

911

912

913

914

915

916

917

918

919

920

921

922


923

924

925

926

927



928

929 **Figure 8. Trimeric HigB(L5ext)HigA<sub>2</sub> is sufficient to repress transcription of *Phig*.** (A)

930 EMSA of HigB(L5ext)HigA<sub>2</sub> binding to O1 DNA (O2 scrambled; *left*) or to O2 DNA (O1

931 scrambled; *right*). (B) β-gal assays of *E. coli* BW25113 transformed with either pQF50-*Phig-*

932 *lacZ* (*Phig* only), pQF50-*Phig-higBhigA-lacZ* (*higBhigA*), pQF50-*Phig-higB(L5ext)higA-lacZ*

933 (*higB(L5ext)higA*), and/or pBAD33-*higB(H54A)*. *Phig* only demonstrates the maximum

934 amount of β-gal activity (black bar, 0% repression). Constructs containing either a wild-type

935 HigBhigA (grey bars) or a HigB(L5ext)HigA variant (pink bars) both repress transcription

936 (first bar in each group). Excess HigB expression (using a catalytically inactive H54A variant)

937 results in little difference in repression (second bars). Error bars represent the mean ± SD

938 of values of three independent experiments (raw values shown as dots).

939

940